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Abstract
Background: 600 mcg of oral misoprostol reduces the incidence of postpartum haemorrhage (PPH), but in previous
research this medication has been administered by health workers. It is unclear whether it is also safe and effective
when self-administered by women.
Methods: This placebo-controlled, double-blind randomised trial enrolled consenting women of at least 34 weeks
gestation, recruited over a 2-month period in Mbale District, Eastern Uganda. Participants had their haemoglobin
measured antenatally and were given either 600mcg misoprostol or placebo to take home and use immediately after
birth in the event of delivery at home. The primary clinical outcome was the incidence of fall in haemoglobin of over
20 % in home births followed-up within 5 days.
Results: 748 women were randomised to either misoprostol (374) or placebo (374). Of those enrolled, 57 % delivered at
a health facility and 43 % delivered at home. 82 % of all medicine packs were retrieved at postnatal follow-up and 97 %
of women delivering at home reported self-administration of the medicine. Two women in the misoprostol group took
the study medication antenatally without adverse effects. There was no significant difference between the study groups
in the drop of maternal haemoglobin by >20 % (misoprostol 9.4 % vs placebo 7.5 %, risk ratio 1.11, 95 % confidence
interval 0.717 to 1.719). There was significantly more fever and shivering in the misoprostol group, but women found
the medication highly acceptable.
Conclusions: This study has shown that antenatally distributed, self-administered misoprostol can be appropriately
taken by study participants. The rarity of the primary outcome means that a very large sample size would be required
to demonstrate clinical effectiveness.
Trial registration: This study was registered with the ISRCTN Register (ISRCTN70408620).
Background
Postpartum haemorrhage (PPH) is one of the most com-
mon causes of maternal mortality worldwide [1]. It is
responsible for around 30 % of maternal deaths, equivalent
to 86,000 deaths per year annually or 10 deaths every hour.
An important strategy in the prevention of postpartum
bleeding is the prophylactic use of uterotonic drugs. The
most commonly used drug is oxytocin, but its public
health impact is limited by the need for parenteral admin-
istration by a health worker and a limited shelf life if not
refrigerated. Misoprostol has been recognized as an option
for preventing PPH in home births, as it is economical, heat
stable, has a long shelf life, and can be taken orally. A meta-
analysis of randomized studies comparing prophylactic use
of misoprostol vs. nothing in community births assisted by
traditional birth attendants (TBAs) or midwives shows a
reduction in severe PPH rate [2]. Population coverage can
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be increased by the antenatal provision of misoprostol to
women for self-administration at the time of delivery [3].
This strategy has been implemented by several pro-
grammes, which have reported reductions in PPH [4, 5].
Although misoprostol appears to be safe and effective
in the community when administered by trained health
workers [6–9], there have been concerns expressed
about the risks of self-administration [10]. Furthermore,
there is no evidence from randomized controlled trials
(RCTs) on the benefits or risks of a strategy of advance
distribution for self-administration [11]. To realize the
benefits of self-administration, women need to ensure
they have the medicine accessible at the time of delivery,
and they need to swallow the medicine at the appropri-
ate time. Concerns regarding this strategy include the
possibility of discouraging facility deliveries, delaying
treatment seeking, producing unmanageable side effects,
and endangering a woman’s health through mis-timed
administration. If these problems occurred, they could
negate the benefits of widespread access to an effective
uterotonic agent. If so, then the efficacy shown in clin-
ical trials in which health workers administer the miso-
prostol may not translate into effectiveness in practice
following its advance distribution for self-administration.
A randomised trial was therefore proposed in order to
address the unanswered questions and concerns about
the safety, effectiveness and feasibility of distributing mi-
soprostol tablets in advance to women for self-use in
home births to prevent PPH.
Methods
In June 2008, misoprostol was approved by the Ministry
of Health for the prevention and treatment of PPH in
Uganda. Use by women for self-administration, however,
is not currently practiced or promoted in Uganda. Fur-
thermore, the policy of the Ministry has been to increase
institutional births and not to encourage home births
assisted by TBAs or village health workers.
Study population
The study was conducted in Mbale district, Eastern
Uganda, with recruitment in Mbale Regional Referral
Hospital and 3 large health centres (Busiu, Lwangoli and
Siira). The overall antenatal attendance is 95 % but only
57 % of women deliver in a health facility [12].
A list of 200 eligible villages that were served by the
participating health facilities and had active village
health teams (VHTs) was drawn up. All pregnant
women at >34 weeks of gestation living in the recruit-
ment villages were eligible to participate. This gesta-
tion was chosen so as to recruit women as close as
possible to the date of birth whilst accepting an under-
lying rate of preterm birth and the inaccuracies of dat-
ing based on last menstrual period alone. Women with
a known allergy to misoprostol or other prostaglandin,
or under 18 years old (unless she was an emancipated
minor) were excluded. Women at risk of experiencing
a delivery complication were not excluded.
Study objectives
The study objective was to pilot the study design for a pos-
sible larger study, including the logistics of community
antenatal distribution of misoprostol and the feasibility of
following-up participants. We also sought to determine the
recruitment rate and the incidence of adverse events to
provide data for sample size determination. No formal
sample size calculation was conducted. Instead, the recruit-
ment was time-limited to 2 months. During the recruit-
ment period, the investigators together with the chairs of
the Trial Steering Committee and Data Monitoring Com-
mittee (DMC) agreed on an a priori data analysis plan to
examine the clinical effectiveness and safety of self-
administered misoprostol, as well as compliance and feasi-
bility around antenatal distribution and self-use of the
medicine. This plan was developed in order to reduce the
risk of bias inherent in post hoc changes, and forms the
basis for the data analysis in this paper.
Consent procedures
Ethical approval was obtained from the Liverpool School
of Tropical Medicine Research and Ethics Committee (ref:
11 · 62) and the Mbale Referral Hospital Institutional Re-
view Committee (ref: REIRC 010/2011). Posters were
placed in the antenatal clinics and formal announcements
made at the daily antenatal clinic to inform women about
the study. Eligible women attending antenatal clinic
received an information sheet before signing informed
consent (or indicating consent with a mark as necessary).
All study documents were available in English and the 3
local languages (Lugisu, Lugwere and Ateso) and were
read aloud to women unable to read.
Study procedures
Women who agreed to participate had an initial capil-
lary haemoglobin measurement (Hemocue®, Angelholm,
Sweden) taken at the time of enrolment during their
third trimester antenatal care (ANC) visit. At this time,
participants were randomized and given a small purse
with a string that could be hung around the neck con-
taining a packet with 3 foil-packed tablets (misoprostol
or placebo) along with an instruction sheet with both
pictorial and written instructions on how to take the
tablets (Fig. 1). The packets were consecutively numbered
according to a computer generated blocked randomisation
code and contained either misoprostol 600 mcg (three 200
mcg tablets; GyMiso®) or identical placebo prepared by
Linepharma (Paris, France). Both women and providers
were blinded to study group assignment.
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Fig. 1 Pictorial instructions on how to take the tablets given to women antenatally along with the medicine packet (the first page had detailed
instructions on study procedures)
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Women were taught to self-administer the medication
orally, immediately after childbirth before the delivery of
the placenta, and after confirming the absence of a twin,
if they delivered at home. They were asked to retain the
drug packaging following the birth, whether they took
the medication (e.g. opened foil blisters) or not (e.g.
sealed, unused packet). At recruitment, women were
also educated about PPH and the importance of seeking
care immediately if excessive bleeding is observed during
a home delivery. The teaching materials developed and
used by JHPIEGO in their community studies [4, 5] were
the basis for those used in this study.
Women who went to hospital or health centres to de-
liver were advised not to take the tablets but to return
the randomisation envelope to the health centre staff.
The study team visited local health facilities each week
to determine if any of the participants had delivered at
that facility and to collect any unused/returned study
medication.
After recruitment into the study, the participants con-
tinued to receive the standard antenatal care from the
local antenatal clinic (including universal iron therapy,
de-worming pills, tetanus toxoid and anti-malarial tab-
lets). The study protocol did not include the provision of
additional services beyond those already available at the
clinic. All women were advised to deliver in a health facil-
ity as per national guidelines.
Following the recruitment of any rural woman, a VHT
member in the participant’s village was informed and asked
to keep in close contact with the study participant. Partici-
pants were also asked to remain in contact with the study
team. Soon after delivery the VHT, clinic midwife or the
woman herself were asked to contact the study team. The
study team also contacted any women who had passed
their estimated delivery date to identify those who had
delivered. Researchers then visited the participant (ideally
at 3–5 days after birth) either at home or in the health fa-
cility to assess the health of the mother and baby. A further
capillary blood sample was taken to measure the change in
haemoglobin level. Multiple other studies use this time for
postnatal haemoglobin assessment [8, 9, 13, 14], as it is the
lowest point for haemoglobin postnatally [15].
Outcome measurement
Background and delivery characteristics, including whether
the study medicine was self-administered and the timing
of administration, were recorded for all participants. The
primary clinical outcome was haemoglobin fall of over
20 %. Other haemoglobin outcomes included the mean
change in haemoglobin and the rate of postnatal anaemia.
Secondary clinical outcomes included the rate of poor ma-
ternal and fetal health, self-reported side effects, and safety
(to include transfer to hospital, surgical intervention, blood
transfusion and maternal death). At follow up, women
were also asked to describe their perceived blood loss after
birth, as well as respond to a series of questions that
assessed the wellbeing of the mother and baby during the
immediate postnatal period. This paper presents the main
clinical and safety outcomes of the study, as well as partici-
pant compliance and the feasibility of self-administered
misoprostol for the prevention of PPH among home births.
Self-assessed blood loss and quality of life measures will be
reported separately.
The analysis of Hb outcomes was a per protocol ana-
lysis confined to those who gave birth outside of an in-
stitution and who were followed up within 5 days. All
other analyses included a ‘modified intention-to-treat’
group (analysing all women who were followed-up), and
an analysis limited to those women followed up after a
non-institutional birth. The data were analysed using
SPSS statistics (version 21).
Any serious adverse events up to the time of follow-up
were reported to the chair of the DMC and Gynuity
Health Projects in accordance with the pharmacovigilance




Overall, 748 women were recruited to the study over the
two month period 23rd May 2012 to 17th July 2012. All eli-
gible women consented to be in the study. The median
(IQR) age of participants was 25 (21–30) years. Nearly
75 % of women were housewives; 93 % had completed
primary education and 40 % had completed secondary
education or higher. Review of the background charac-
teristics shows that there were no differences between
the study groups (Table 1), either as a whole, amongst
those who had home births or for all women followed
up (data not shown).
Follow-up data were obtained for 700 (93 · 2 %) of the
women recruited (Fig. 2). The overall home birth rate
was 43 % (Table 2). The median (IQR) time to follow up
was 4 (3–17) days.
Medication use and safety
The study medication was reported having been taken
by 290/299 = 97 · 0 % of mothers who gave birth at home
and by 107/401 = 26 · 7 % of those who delivered in facil-
ities (overall 56 · 7 %, Table 2). Medication packets (used
and unused) were retrieved from most women who were
followed up (575/700 = 82 · 1 %). The majority of women
who took the study medication did so without assistance
(74 · 3 %). Only 1 woman delivering at home did not
have the medication with her at the time of the birth. In
total, fifteen (2.1 %) women had multiple births; 5
women who delivered twins at home took the study
medication correctly, after delivery of the second twin.
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Among all women followed up, two women took the
medication prior to the delivery of a singleton baby.
Both had been randomised to misoprostol. One had vis-
ited a nearby TBA with ‘false labour pains’ and was
instructed by the TBA to take the tablets immediately.
She gave birth at a government clinic 6 days later. The
other woman delivered at the home of a TBA and took
the study medication during labour, one tablet before
and two tablets after the delivery. Both had uncompli-
cated vaginal deliveries with no reported neonatal
complications.
In the misoprostol arm, three women were hospita-
lised postnatally for postpartum haemorrhage; one of
these women received a blood transfusion. All three
women had facility births, did not take the study medi-
cation, and were subsequently discharged. There was 1
maternal death in a previously healthy parous woman,
who had laboured at a health centre where there was no
qualified midwife present. She had marked intrapartum
blood loss and continued to bleed postnatally. She was
not given any medication and was referred to Mbale Re-
gional Referral Hospital, but died in transit. The study
drugs (misoprostol) were not taken, but later retrieved
from the caregiver. Lastly, one woman who was random-
ized to receive misoprostol but did not take the study
medication was hospitalised postnatally following inci-
sion and drainage for a breast abscess.
In the placebo group, two women had postpartum
haemorrhage (one of whom was transfused), 1 woman
had a subtotal hysterectomy following a ruptured uterus,
and 1 had an abdominal dehiscence following emergency
caesarean section. All were facility births.
Haemoglobin outcomes
Antenatal haemoglobin levels for all the women enrolled
varied between 5 · 8 and 14 · 8 g/dl with a mean (s.d.) of
11 · 2 (1 · 4) g/dl, while postnatal values varied between
4 · 4 and 15 · 8 g/dl with a mean (s.d.) of 11 · 4 (1 · 6).
The main group of interest were the 177 women who
delivered outside of a formal health facility and had
haemoglobin outcomes assessed within 5 days of deliv-
ery. There was no significant difference between the groups
for the primary outcome of a fall in haemoglobin >20 %
(misoprostol 9 · 4 % vs placebo 7 · 5 %, relative risk 1 · 11,
95 % confidence interval 0 · 72 to 1 · 72; Table 3). The mean
change in haemoglobin was similar in the two groups
(−0 · 06 vs −0 · 09; mean difference 0 · 03, 95 % CI −0 · 47
to 0 · 53). Similar results were found for those women
who had home births and were followed up at any point
in time postnatally (data not shown).
Clinical outcomes
Clinical maternal complications were rare among the co-
hort delivering at home (n = 299). No woman had a
postnatal blood transfusion and only one had a subse-
quent surgical procedure (incision of a breast abscess).
Seven women were given other/additional uterotonics by
their birth attendant at home (misoprostol arm n = 3;
placebo arm n = 4). Two women reported that they
sought higher level of care for postpartum bleeding. One
had delivered en route to the hospital and had not taken
the study medication. She experienced heavy bleeding
and when she reached the facility she was hospitalized
for 3 days due to severe anaemia (Hb level 6.0 g/dL).
Another woman in the placebo arm reported that she
had consulted a health professional after having continu-
ous bleeding for several days after delivery; she was diag-
nosed and treated for a urinary tract infection. There
Table 1 Background characteristics for all women recruited into
the study (n = 748)
Misoprostol Placebo
Number of women 374 374
Site of recruitment (n, %):
Mbale Regional Referral Hospital 157 (42.0) 153 (40.9)
Busiu (level IV health centre) 119 (31.8) 119 (31.8)
Lwangoli (level III health centre) 56 (15.0) 54 (14.4)
Siira (level III health centre) 42 (11.2) 48 (12.8)
Age (mean, SD) 26.4 (6.2) 26.2 (6.4)
Primary occupation (n, %):
Housewife 277 (74.1) 284 (75.9)
Employed 85 (22.7) 80 (21.4)
Unemployed / student fc12 ( 3.2) 10 ( 2.7)
Highest level of education completed† (n, %):
No education 24 ( 6.4) 27 ( 7.2)
Primary 202 (54.2) 197 (52.7)
Secondary or higher 147 (39.3) 150 (40.1)
Estimated gestational age (mean, SD) 35.3 (1.4) 35.3 (1.5)
Nulliparous (n, %) 81 (21.7) 83 (22.2)
Previous CS deliveries (n, %)
0 365 (97.6) 367 (98.1)
1 7 ( 1.9) 7 ( 1.9)‡







Normal 207 (55.3 %) 214 (57.2 %)
Mild anaemia 136 (36.4 %) 127 (34.0 %)
Moderate anaemia 27 ( 7.2 %) 31 ( 8.3 %)
Severe anaemia* 3 ( 0.8 %) 2 ( 0.5 %)
† : not recorded for 1 participant in misoprostol group
‡: the number of previous CS was not recorded for one participant and a
single CS was assumed
* : anaemia shown by WHO classification: normal (>11 g/dl), mild (9–10.99
g/dl), moderate (7–8.99 g/dl) and severe (<7 g/dl). Data is missing for one
participant in the misoprostol arm
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was one stillbirth and 3 neonatal deaths, all in the pla-
cebo group. Shivering was significantly more common in
the misoprostol group (51 % vs 28 %, RR 1 · 59, 95 % CI
1 · 28 to 1 · 99) as was fever (27 · 2 % vs 14 · 6 %, RR 1 ·
41, 95 % CI 1 · 12 to 1 · 77). Satisfaction rates were high
in both groups with the vast majority (96 · 7 %) stating
that they were satisfied with the medication (misoprostol
96 · 5 % vs placebo 96 · 9 %) and an even larger propor-
tion indicating that they would recommend the prophy-
laxis to a friend (98 · 3 % in both the misoprostol and
placebo groups).
Approximately one-quarter of women who had facility
births also took the study drug (106/401 = 26 %), mainly
due to a lack of availability of oxytocin. We therefore
conducted a post-hoc analysis of all women who took
the medication irrespective of delivery location and tim-
ing of follow up (N = 397). The rate of a >20 % fall in
haemoglobin was similar between the groups (miso-
prostol 4 · 5 % vs placebo 5 · 2 %, RR 0 · 92, 95 % CI 0 ·
57 to 1 · 50).
Discussion
This study allows evaluation of the risks and benefits of
a strategy of antenatal distribution of 600 mcg oral miso-
prostol for self-administration along with collection of
individual-level outcome data for women who took the
medicine following a non-institutional delivery. Overall,
postpartum follow-up in this study was achieved in 93 %
of participants, with 61 % seen within 5 days of delivery.
Participant compliance in taking the prophylactic regimen
at home, as well as women’s satisfaction-levels, were high
(rates exceeding 97 % for both of these feasibility measures).
These results corroborate other documented experiences
about the feasibility of offering misoprostol to women for
self-use at the time of delivery in order to prevent postpar-
tum haemorrhage [3].
The close follow-up in this study has allowed a robust
assessment of how misoprostol may be used in the com-
munity in an advance distribution programme. Only 2 of
the 700 women who were given medicine packets in
their third trimester took the tablets early with a fetus
still in utero. Both of these women delivered healthy
babies despite being in the misoprostol arm. Similarly, a
self-administration study in Liberia saw no adverse
events in the three women who took misoprostol prior
to delivery.[16] While misoprostol use before delivery
has the potential for causing harm, the effect of that
mistimed administration will depend on the clinical situ-
ation and the dose and route of administration [17]. The
potential danger would be increased if the labour were
obstructed already, if she has a previous caesarean sec-
tion scar, or if the baby was in a transverse lie, but these
Fig. 2 CONSORT trial profile
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are comparatively rare. With well-designed programmes
and widespread training of providers, women, and families
on the correct use of this medicine, mistimed administra-
tion can be greatly minimized. Importantly, in our study,
most women took the study drug in the right way after
the birth of the baby(ies). This supports population data
from other larger studies reporting minimal incorrect use
before delivery [3–5, 16]. However, programs should con-
tinue to monitor adverse events to confirm that complica-
tions from early administration are not occurring under
any other circumstances not captured in this study.
While instructions were to take the medicine after the
birth of the baby and before the expulsion of the placenta,
nearly half of women reported taking the tablets after pla-
cental delivery. Similarly, Smith et al. showed nearly a third
of women in a sample in Liberia administered the medicine
late [16]. This might be due to a rapid placental expulsion,
poor recall of precise timing of self-use, or difficulties
achieving this timing in a home setting. However, there is
no reason to believe that uterotonic administration after
placental expulsion would have adverse effects, although it
might delay the onset of action. Optimal timing of utero-
tonic administration is still a question warranting further
research.
One of the strengths of the study is the variation that
was captured with regard to self-administration of the
medicine, as well as the different homebirth delivery sce-
narios. Nearly three-quarters of home deliveries were
unattended by a provider: 65 % (194/299) were assisted
by a family member/friend and 8 % (24/299) did not
have anyone present. Only one-quarter were assisted by
a TBA. Although the homebirth cohort is relatively small
Table 2 Birthplace outcomes – all women followed up (n = 700)
Misoprostol Placebo Relative risk (95 % CI)
Sample size 345 355
Final place of delivery (n, %)
Hospital 102 (29.6) 114 (32.1) —
Government or private clinic 93 (27.0) 92 (25.9) 1.065 (0.871 : 1.302)
Home (own/family member) 125 (36.2) 120 (33.8) 1.076 (0.892 : 1.298)
House of friend or TBA 16 ( 4.6) 19 ( 5.4) 0.968 (0.657 : 1.462)
Other* 9 ( 2.6) 10 ( 2.8) 1.059 (0.668 : 1.678)
Number of babies delivered (n, %)
1 338 (98.0) 347 (97.7) —
2 or more 7 ( 2.0) 8 ( 2.3)† 1.002 (0.981 : 1.024)
Mode of delivery (n, %)
Normal vaginal delivery 328 (95.1) 341 (96.1) —
Caesarean section 16 ( 4.6) 14 ( 3.9) 1.088 (0.772 : 1.534)
Instrumental delivery 1 ( 0.3) 0 —
Person assisting with the birth**(n, %)
Doctor and/or trained midwife 196 (56.8) 207 (58.3) 0.970 (0.836 : 1.125)
Traditional birth attendant 37 (10.7) 39 (11.0) 0.987 (0.782 : 1.245)
Family member and/or friend 106 (30.7) 103 (29.0) 1.041 (0.885 : 1.225)
No-one 12 ( 3.5) 13 ( 3.7) 0.974 (0.664 : 1.410)
Village Health team / Nursing assistant 3 ( 0.9) 4 ( 1.1) 0.886 (0.465 : 1.691)
Study medication taken (n, %) 204 (59.1) 193 (54.4) 1.088 (0.955 : 1.238)
If medication taken when did you take them? (n, %)
Before labour started 1 ( 0.5) 0 —
During labour 1 ( 0.5) 0 —
Immediately after delivery (before placenta) 97 (47.5) 103 (53.4) —
Immediately after delivery (after placenta) 102 (50.0) 87 (45.1) 1.113 (0.916 : 1.351)
1–24 hours after delivery 3 ( 1.5) 3 ( 1.6) 1.031 (0.457 : 2.324)
* : 14 mothers delivered en-route to hospital; 5 mothers delivered at the home of an unspecified health professional
** : more than one response possible so numbers do not total 100 %
† : two participants in the placebo arm recorded singleton births but stated verbally later that they delivered twins. They are both added to the multiple birth
group in this table
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in this study, the ‘unsupervised’ delivery environment pro-
vides important insight on how the medicine may be used
without negative consequence when scaled-up in pro-
grams. Importantly, the results point to the need for im-
proved antenatal counselling for women. Additional
community sensitization activities targeting women and
their families may also be helpful to emphasize key in-
structions about when to take the medicine. However,
these findings and lessons learnt may not be generalizable
to contexts where the delivery environment is different or
for strategies in which drug dissemination occurs in a dif-
ferent way.
Among homebirths in this study, large peripartum falls in
hemoglobin were uncommon and life-threatening PPH
rare. Whilst this is a welcome finding, it makes the conduct
of efficacy trials very difficult. Indeed, a very large trial
would be needed to demonstrate a significant reduction in
PPH outcomes associated with a self-administration strat-
egy. For example, a 25 % relative reduction in ‘fall in
haemoglobin of over 20 %’ from 7 · 5 % to 5 · 6 % would re-
quire 7,120 home births to be followed up within 5 days
(α = 0 · 05; β = 0 · 9). In a setting with an institutional birth
rate of 40–50 %, this might require around 15,000–20,000
recruits, depending on the feasibility of conducting
Table 3 Outcomes from the births of all women who gave birth at home (or family/TBA home). Data on haemoglobin is taken
from those for whom a follow-up assessment was completed within 5 days of delivery
Haemoglobin Measures (women seen within 5 days of delivery)
Misoprostol (n = 97) Placebo (n = 80) Relative risk or mean difference (95 % CI)
Days from birth to follow-up (mean, (SD)) 3.6 (0.7) 3.5 (0.7) 0.07 (−0.14 : 0.28)
Fall in Hb >20 % (n, %) 9 ( 9.4) 6 ( 7.5) 1.110 (0.717 : 1.719)
Fall in Hb > 2 g/dl (n, %) 13 (13.4) 8 (10.0) 1.150 (0.798 : 1.657)
Postnatal Hb g/dl (mean (SD) [range]) 11.1 (1.8) [5.2:15.3] 11.2 (1.4) [6.1:14.0] −0.11 (−0.59 : 0.37)
Anaemia status* (n,%)
Normal 51 (52.6) 46 (57.5) —
Mild 36 (37.1) 28 (35.0) 1.070 (0.803 : 1.426)
Moderate 8 ( 8.2) 5 ( 6.2) 1.170 (0.732 : 1.872)
Severe 2 ( 2.1) 1 ( 1.2) 1.268 (0.557 : 2.885)
Fall in Hb g/dl (mean (SD) [range]) 0.06 (1.82) [−5.5:5.2] 0.09 (1.50) [−3.5:4.0] −0.03 (−0.53 : 0.47)
Maternal and Neonatal Outcomes (all home births)
Misoprostol (n = 150) Placebo (n = 149) Relative risk or mean difference (95 % CI)
Days from birth to follow-up (median (IQR)) 4 (3 – 13) 5 (3 – 25) —
Maternal complications (n, %)†
Health professional consulted 2 ( 1.3) 3 ( 2.0) 0.795 (0.525 : 1.427)
Admitted to a health facility >24 hours** 1 ( 0.7) 1 ( 0.7) 0.997 (0.517 : 1.691)
Surgical procedure since delivery*** 0 1 ( 0.7) —
Retained placenta 3 ( 2.0) 2 ( 1.3) 1.200 (0.581 : 2.477)
Blood transfusion after delivery 0 0 —
Use of additional uterotonics (n, %) 3 (2.0) 4 (2.7) 0.745 (0.189 : 2.928)
Self-reported side effects (n, %)†
Shivering/chills after birth 75 (51.0) 40 (27.8) 1.594 (1.277 : 1.991)
Fever after birth 40 (27.2) 21 (14.6) 1.410 (1.121 : 1.772)
Diarrhoea within 24 hours 4 ( 2.7) 1 ( 0.7) 1.600 (1.017 : 2.518)
Neonatal Death (n, %) 0 3 ( 2.0) —
If ‘yes, when did the baby die? (n, %)
Before birth 0 1 (33.3) —
Within 24 hours of birth 0 0
More than 24 hours after birth 0 2 (66.7)
* Anaemia shown by WHO classification: normal (>11 g/dl), mild (9–10.99 g/dl), moderate (7.8.99 g/dl) and severe (<7 g/dl).
** Misoprostol: admitted with Hb <6 g/dl; placebo: admitted for drainage of breast abscess
*** Drainage of breast abscess
† Respondents could have more than one response. Data missing for 3 in the misoprostol group and 5 in the placebo group.
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postpartum follow-up visits within 5 days. Our time-
limited study was not designed to assess the clinical effect-
iveness of misoprostol (700 women has only 17 % power
to detect a fall in Hb of over 20 % from 7.5 % to 5.6 %, α
= 0.05), and we found no statistically significant difference
between the groups.
Conclusions
On the basis of the data from this and other studies,
there are no reasons to prevent a policy of antenatal dis-
tribution of misoprostol for self-administration. This
conclusion is based on three factors:
1. Since MamaMiso was conceived, a large placebo-
controlled study has been published [8], and there
has also been ongoing experience with antenatal
distribution of misoprostol [3–5, 11, 18, 19].
Meta-analysis of randomised trials now shows that
community misoprostol reduces postpartum
haemorrhage [2].
2. The remaining issue has been whether the potential
problems with self-administration (women not having
the medication with them at the time of labour or
taking it incorrectly) would negate the benefits of
widespread access to misoprostol in home birth
settings. In this study we found that participants
did have the medication with them at the time of
delivery and were able to take the misoprostol
appropriately after birth (albeit with many delaying
it until after the delivery of the placenta). These
data, combined with that of Smith [3] are strongly
suggestive that the efficacy seen when health
workers administer misoprostol in the community
will also be seen when women self-administer the
drug themselves.
3. Rare adverse events are best detected through
observational studies or reporting systems, but
individual randomized trials are also important to
pick up more common but less severe safety
problems. The safety demonstrated in this study adds
to the safety data from other large observational studies
[3–5, 16, 18, 19].
In conclusion, this study has shown that antenatally dis-
tributed, self-administered misoprostol can be safely taken
by study participants. With careful counselling and moni-
toring of adverse events, programmes may move beyond
safety concerns and focus on other implementation issues
such as ensuring that the right population of women is
reached and optimizing community education activities.
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